Arcus Biosciences Q1 2026 Earnings Call Highlights Key Developments in Cascadifan Program
Arcus Biosciences (RCUS) reported progress in its lead program, cascadifan, with full ownership and a projected $5 billion peak sales opportunity in kidney cancer. The company is advancing its Phase 3 trials and plans to initiate a first-line study by year-end 2026.
Tickers: $RCUS
Topics: cancer clinical trials drug ownership market opportunity RCC